Skip to main content
Top
Published in: Italian Journal of Pediatrics 1/2023

Open Access 01-12-2023 | Muscular Dystrophy | Research

Association between blood eosinophil count and Duchenne muscular dystrophy severity and prognosis: a retrospective cohort study

Authors: Zhi Jiang, Hongmei Liao, Liwen Wu, Wenjing Hu, Liming Yang, Bo Chen, Zeshu Ning, Jingwen Tang, Rong Xu, Mei Chen, Feng Guo, Shulei Liu

Published in: Italian Journal of Pediatrics | Issue 1/2023

Login to get access

Abstract

Background

Duchenne muscular dystrophy (DMD) is a rare hereditary muscular disease. The role of eosinophils in DMD has not been clarified. This study aims to evaluate the association between peripheral blood eosinophil count and severity and prognosis of DMD.

Methods

A retrospective cohort study was performed for 145 DMD patients between January 2012 and December 2020. Clinical data of 150 healthy children were collected as a control group. Logistic regression and Cox regression analyses were used to explore the influences of eosinophil count on DMD severity and prognosis.

Results

Eosinophil count in DMD group was lower than the control group (Z = 2.163, P = 0.031). It was negatively correlated with Vignos scale score, Spearman correlation coefficient was p = 0.245, P = 0.040 (at admission), p = 0.137, P = 0.032 (at follow-up); was a protective factor for high Vignos scale score at admission [odds ratio (OR) = 0.038, 95%CI: 0.002–0.752, P = 0.032] and follow-up (OR = 0.033,95%CI: 0.001–0.121, P = 0.039). The Cox regression analysis indicated that elevated eosinophil count was correlated with better therapeutic efficacy for DMD patients [hazard ratio (HR) = 2.218, 95%CI: 1.154–3.924, P = 0.016].

Conclusion

Eosinophil count in peripheral blood was correlated with the severity of DMD. It could indicate the therapeutic efficacy and prognosis of DMD patients to a certain extent. Eosinophils may be a potentially valuable biomarker or therapeutic target for DMD.
Literature
1.
go back to reference Gartz M, Lin CW, Sussman MA, Lawlor MW, Strande JL. Duchenne muscular dystrophy (DMD) cardiomyocyte-secreted exosomes promote the pathogenesis of DMD-associated cardiomyopathy. Dis Model Mech. 2020;13(11):dmm045559. Gartz M, Lin CW, Sussman MA, Lawlor MW, Strande JL. Duchenne muscular dystrophy (DMD) cardiomyocyte-secreted exosomes promote the pathogenesis of DMD-associated cardiomyopathy. Dis Model Mech. 2020;13(11):dmm045559.
2.
go back to reference Kastenschmidt JM, Coulis G, Farahat PK, Pham P, Rios R, Cristal TT, et al. A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis associated gene expression. Cell Rep. 2021;35(2): 108997.CrossRefPubMedPubMedCentral Kastenschmidt JM, Coulis G, Farahat PK, Pham P, Rios R, Cristal TT, et al. A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis associated gene expression. Cell Rep. 2021;35(2): 108997.CrossRefPubMedPubMedCentral
3.
go back to reference Cruz-Guzmán Odel R, Rodríguez-Cruz M, Escobar Cedillo RE. Systemic Inflammation in Duchenne Muscular Dystrophy: Association with Muscle Function and Nutritional Status. Biomed Res Int. 2015;2015: 891972.PubMed Cruz-Guzmán Odel R, Rodríguez-Cruz M, Escobar Cedillo RE. Systemic Inflammation in Duchenne Muscular Dystrophy: Association with Muscle Function and Nutritional Status. Biomed Res Int. 2015;2015: 891972.PubMed
4.
go back to reference Lecompte S, Abou-Samra M, Boursereau R, Noel L, Brichard SM. Skeletal muscle secretome in Duchenne muscular dystrophy: a pivotal anti-inflammatory role of adiponectin. Cell Mol Life Sci. 2017;74(13):2487–501.CrossRefPubMedPubMedCentral Lecompte S, Abou-Samra M, Boursereau R, Noel L, Brichard SM. Skeletal muscle secretome in Duchenne muscular dystrophy: a pivotal anti-inflammatory role of adiponectin. Cell Mol Life Sci. 2017;74(13):2487–501.CrossRefPubMedPubMedCentral
5.
go back to reference Farini A, Sitzia C, Cassani B, Cassinelli L, Rigoni R, Colleoni F, et al. Therapeutic potential of immunoproteasome inhibition in Duchenne muscular dystrophy. MolTher. 2016;24(11):1898–912. Farini A, Sitzia C, Cassani B, Cassinelli L, Rigoni R, Colleoni F, et al. Therapeutic potential of immunoproteasome inhibition in Duchenne muscular dystrophy. MolTher. 2016;24(11):1898–912.
6.
go back to reference Bello L, Pegoraro E. The, “Usual Suspects”: Genes for inflammation, fibrosis, regeneration, and muscle strength modify Duchenne muscular dystrophy. J Clin Med. 2019;8(5):649.CrossRefPubMedPubMedCentral Bello L, Pegoraro E. The, “Usual Suspects”: Genes for inflammation, fibrosis, regeneration, and muscle strength modify Duchenne muscular dystrophy. J Clin Med. 2019;8(5):649.CrossRefPubMedPubMedCentral
8.
go back to reference Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao V, et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med.2015;7(299):299rv294. Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao V, et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med.2015;7(299):299rv294.
9.
go back to reference Donovan JM, Zimmer M, Offman E, Grant T, & JirousekM. A novelNF-ka-ppaB inhibitor, Edasalonexent (CAT-1004), in development as a disease-modifying treatment for patients with Duchenne muscular dystrophy: Phase 1 safety, pharmacokinetics, and pharmacod-ynamicsin adult subjects. J Clin Pharmacol,2017;57(5):627–639. Donovan JM, Zimmer M, Offman E, Grant T, & JirousekM. A novelNF-ka-ppaB inhibitor, Edasalonexent (CAT-1004), in development as a disease-modifying treatment for patients with Duchenne muscular dystrophy: Phase 1 safety, pharmacokinetics, and pharmacod-ynamicsin adult subjects. J Clin Pharmacol,2017;57(5):627–639.
11.
go back to reference Moreira A, Leisgang W, Schuler G, Heinzerling L. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy. 2017;9(2):115–21.CrossRefPubMed Moreira A, Leisgang W, Schuler G, Heinzerling L. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy. 2017;9(2):115–21.CrossRefPubMed
12.
go back to reference Fuschillo S, Molino A, Stellato C, Motta A, Maniscalco M. Blood eosinophils as biomarkers of therapeutic response to chronic obstructive pulmonary disease: still work in progress. Eur J Intern Med. 2019;68:1–5.CrossRefPubMed Fuschillo S, Molino A, Stellato C, Motta A, Maniscalco M. Blood eosinophils as biomarkers of therapeutic response to chronic obstructive pulmonary disease: still work in progress. Eur J Intern Med. 2019;68:1–5.CrossRefPubMed
13.
go back to reference Okauchi S, Shiozawa T, Miyazaki K, Nishino K, Sasatani Y, Ohara G, et al. Association between peripheral eosinophils and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Pol Arch Intern Med. 2021;131(2):152–60.PubMed Okauchi S, Shiozawa T, Miyazaki K, Nishino K, Sasatani Y, Ohara G, et al. Association between peripheral eosinophils and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. Pol Arch Intern Med. 2021;131(2):152–60.PubMed
14.
go back to reference Heredia JE, Mukundan L, Chen FM, Mueller AA, Deo RC, Locksley RM, et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell. 2013;153(3):376–88.CrossRefPubMedPubMedCentral Heredia JE, Mukundan L, Chen FM, Mueller AA, Deo RC, Locksley RM, et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell. 2013;153(3):376–88.CrossRefPubMedPubMedCentral
15.
go back to reference Bartlett EK, Flynn JR, Panageas KS, Ferraro RA, Sta Cruz JM, Postow MA, et al. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer. 2020;126(1):76–85.CrossRefPubMed Bartlett EK, Flynn JR, Panageas KS, Ferraro RA, Sta Cruz JM, Postow MA, et al. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer. 2020;126(1):76–85.CrossRefPubMed
16.
go back to reference Lv MY, Qiang LX, Li ZH, Jin SD. The lower the eosinophils, the stronger the inflammatory response? The relationship of different levels of eosinophils with the degree of inflammation in acute exacerbation chronic obstructive pulmonary disease (AECOPD). J Thorac Dis. 2021;13(1):232–43.CrossRefPubMedPubMedCentral Lv MY, Qiang LX, Li ZH, Jin SD. The lower the eosinophils, the stronger the inflammatory response? The relationship of different levels of eosinophils with the degree of inflammation in acute exacerbation chronic obstructive pulmonary disease (AECOPD). J Thorac Dis. 2021;13(1):232–43.CrossRefPubMedPubMedCentral
18.
go back to reference Schröder T, Fuchss J, Schneider I, Stoltenburg-Didinger G, Hanisch F. Eosinophils in hereditary and inflammatory myopathies. Acta Myol. 2013;32(3):148–53.PubMedPubMedCentral Schröder T, Fuchss J, Schneider I, Stoltenburg-Didinger G, Hanisch F. Eosinophils in hereditary and inflammatory myopathies. Acta Myol. 2013;32(3):148–53.PubMedPubMedCentral
19.
go back to reference Sek AC, Moore IN, Smelkinson MG, Pak K, Minai M, Smith R, et al. Eosinophils do not drive a acute muscle pathology in the mdx mouse model of Duchenne muscular dystrophy. J Immunol. 2019;203(2):476–84.CrossRefPubMed Sek AC, Moore IN, Smelkinson MG, Pak K, Minai M, Smith R, et al. Eosinophils do not drive a acute muscle pathology in the mdx mouse model of Duchenne muscular dystrophy. J Immunol. 2019;203(2):476–84.CrossRefPubMed
20.
go back to reference Lu M, Taylor BV, Körner H. Genomic effects of the vitamin D receptor: potentially the link between vitamin D, immune cells, and multiple sclerosis. Front Immunol. 2018;9:477.CrossRefPubMedPubMedCentral Lu M, Taylor BV, Körner H. Genomic effects of the vitamin D receptor: potentially the link between vitamin D, immune cells, and multiple sclerosis. Front Immunol. 2018;9:477.CrossRefPubMedPubMedCentral
22.
go back to reference Soslow JH, Markham LW, Burnette WB, Galindo CL, Feoktistov I, Raucci FJ, et al. Increased number of circulating CD8/CD26T cellsinthe blood of Duchenne muscular dystrophy patients is associated with augmented binding of ddenosine deaminase and higher Muscular strength scores. Front Pharmacol. 2017;8:914.CrossRefPubMedPubMedCentral Soslow JH, Markham LW, Burnette WB, Galindo CL, Feoktistov I, Raucci FJ, et al. Increased number of circulating CD8/CD26T cellsinthe blood of Duchenne muscular dystrophy patients is associated with augmented binding of ddenosine deaminase and higher Muscular strength scores. Front Pharmacol. 2017;8:914.CrossRefPubMedPubMedCentral
23.
go back to reference Pinto-Mariz F, Rodrigues Carvalho L, Prufer De Queiroz Campos Araujo A, De Mello W, Gonçalves Ribeiro M, Cunha Mdo C, et al. CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy. Skeletal Muscle. 2015;5:45. Pinto-Mariz F, Rodrigues Carvalho L, Prufer De Queiroz Campos Araujo A, De Mello W, Gonçalves Ribeiro M, Cunha Mdo C, et al. CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy. Skeletal Muscle. 2015;5:45.
24.
go back to reference Kharraz Y, Guerra J, Mann CJ, Serrano AL, Muñoz-Cánoves P. Macrophage plasticity and the role of inflammation in skeletal muscle repair. Mediators Inflamm. 2013;2013: 491497.CrossRefPubMedPubMedCentral Kharraz Y, Guerra J, Mann CJ, Serrano AL, Muñoz-Cánoves P. Macrophage plasticity and the role of inflammation in skeletal muscle repair. Mediators Inflamm. 2013;2013: 491497.CrossRefPubMedPubMedCentral
25.
go back to reference Mojumdar K, Liang F, Giordano C, Lemaire C, Danialou G, Okazaki T, et al. Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CC-R2. EMBO Mol Med. 2014;6(11):1476–92.CrossRefPubMedPubMedCentral Mojumdar K, Liang F, Giordano C, Lemaire C, Danialou G, Okazaki T, et al. Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CC-R2. EMBO Mol Med. 2014;6(11):1476–92.CrossRefPubMedPubMedCentral
26.
go back to reference McDonaldCM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, et al. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve. 2020;61(1):26–35. McDonaldCM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, et al. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. Muscle Nerve. 2020;61(1):26–35.
27.
go back to reference Flanigan KM, Campbell K, Viollet L, Wang W, Gomez AM, Walker CM, et al. Anti-Dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther. 2013;24(9):797–806.CrossRefPubMedPubMedCentral Flanigan KM, Campbell K, Viollet L, Wang W, Gomez AM, Walker CM, et al. Anti-Dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther. 2013;24(9):797–806.CrossRefPubMedPubMedCentral
28.
go back to reference Kameyama T, Ohuchi K, Funato M, Ando S, Inagaki S, Sato A. et al. Efficacy of prednisolone in generated myotubes derived from fibroblasts of Duchenne muscular dystrophy patients. Front Pharmacol. 2018; 9:1402. Kameyama T, Ohuchi K, Funato M, Ando S, Inagaki S, Sato A. et al. Efficacy of prednisolone in generated myotubes derived from fibroblasts of Duchenne muscular dystrophy patients. Front Pharmacol. 2018; 9:1402.
29.
go back to reference Herbelet S, Rodenbach A, Paepe B, DeBleecker JL. Anti-Inflammatory and general glucocorticoid physiology in skeletal muscles affected by Duchenne muscular dystrophy: exploration of steroid sparing agents. Int J Mol Sci. 2020;21(13):4596.CrossRefPubMedPubMedCentral Herbelet S, Rodenbach A, Paepe B, DeBleecker JL. Anti-Inflammatory and general glucocorticoid physiology in skeletal muscles affected by Duchenne muscular dystrophy: exploration of steroid sparing agents. Int J Mol Sci. 2020;21(13):4596.CrossRefPubMedPubMedCentral
Metadata
Title
Association between blood eosinophil count and Duchenne muscular dystrophy severity and prognosis: a retrospective cohort study
Authors
Zhi Jiang
Hongmei Liao
Liwen Wu
Wenjing Hu
Liming Yang
Bo Chen
Zeshu Ning
Jingwen Tang
Rong Xu
Mei Chen
Feng Guo
Shulei Liu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue 1/2023
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-023-01483-y

Other articles of this Issue 1/2023

Italian Journal of Pediatrics 1/2023 Go to the issue